Today, StockMatusow.com has released its biotech research report on pSivda Corporation.
Online PR News – 03-December-2013 – Henderson, Nevada – StockMatusow's analysis and research primarily focuses on developmental biotechs that are under speculated which could offer investors large returns over time. pSivda, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back of the eye. Ophthalmology treatments is a fast growing segment in healthcare, with age-related macular degeneration (AMD) and diabetic retinopathy segment of that market generating just over $3 billion in 2010. Visiongain projects those revenues to climb to nearly $5.1 billion by 2014 while ten-year forecasts for ocular disease therapeutics predict steady growth.
pSivda offers ILUVIEN, an injectable sustained-release micro-insert delivering fluocinolone acetonide for the treatment of vision impairment associated with chronic diabetic macular edema (DME); and Retisert for the treatment of posterior uveitis.
The report focuses on the upcoming Food and Drug Administration (FDA) Advisory Committee (ADCOM) meeting on January 27, 2014 and its task to identify a patient population that could benefit from ILUVIEN. A properly identified patient population could lead to a positive recommendation to the FDA for approval. If the FDA ultimately approves ILUVIEN, pSivda stands to gain over $25M in licensing payments.
To read the full and free report on pSivda, follow this link here.
StockMatusow.com offers research into primarily developmental biotech companies. It also offers opinions on how to properly trade and invest in the stock market. StockMatusow also offers investing and trading education via online webinars for premium membership on the site.